ExcelMale
Menu
Home
What's new
Latest activity
Forums
New posts
Search forums
What's new
New posts
Latest activity
Videos
Lab Tests
Doctor Finder
Buy Books
About Us
Men’s Health Coaching
Log in
Register
What's new
Search
Search
Search titles only
By:
New posts
Search forums
Menu
Log in
Register
Navigation
Install the app
Install
More options
Contact us
Close Menu
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Male Hypogonadism- Low Testosterone: Treatment Choices
JavaScript is disabled. For a better experience, please enable JavaScript in your browser before proceeding.
You are using an out of date browser. It may not display this or other websites correctly.
You should upgrade or use an
alternative browser
.
Reply to thread
Message
<blockquote data-quote="madman" data-source="post: 191269" data-attributes="member: 13851"><p><strong>Male hypogonadism: <span style="color: rgb(184, 49, 47)">therapeutic choices and pharmacological management</span> </strong></p><p><span style="color: rgb(44, 130, 201)">Sandro LA VIGNERA, Giulia IZZO, Gian P. EMERENZIANI, Rossella CANNARELLA , Rosita A. CONDORELLI, Aldo E. CALOGERO, Antonio AVERSA </span></p><p></p><p></p><p><strong>ABSTRACT</strong></p><p></p><p><em><span style="color: rgb(184, 49, 47)">Male hypogonadism, defined as an inadequate testosterone production, recognizes a testicular (primary hypogonadism) or a hypothalamic-pituitary dysfunction (central hypogonadism), although combined forms can also occur. </span></em><span style="color: rgb(44, 130, 201)">Moreover, it has been known that intensive exercise training might be a cause of functional hypogonadism. </span><span style="color: rgb(184, 49, 47)"><em>Many therapeutic choices are currently available, depending on the timing of hypogonadism onset and fertility issues. </em></span><span style="color: rgb(44, 130, 201)"><em>The aim of this review was to comprehensively supply therapeutic options and schemes currently available for male hypogonadism, including pharmacological management of primary and central forms. Evidence on testosterone formulations, human chorionic gonadotropin, selective estrogen receptor modulators, and aromatase inhibitors will be provided.</em></span></p><p></p><p><span style="color: rgb(184, 49, 47)"><em>Male hypogonadism is a clinical syndrome characterized by failure of the testes to produce an adequate amount of testosterone (T) and/or a normal number of spermatozoa.</em></span> <span style="color: rgb(44, 130, 201)"><em>It can be classified according to the site of hypothalamic-pituitary dysfunction, the involvement of testicular cell population, and the time of its onset. </em></span><span style="color: rgb(184, 49, 47)"><em>Also, hypogonadism can be organic or dysfunctional. The former is caused by congenital, structural or destructive disorders, whereas the latter refers to potentially reversible conditions.1</em></span> <span style="color: rgb(44, 130, 201)"><em>Hypogonadism is further classified into primary or central forms, based on the presence of a dysfunction at the testicular or the hypothalamic-pituitary level.1, 2</em></span> <span style="color: rgb(184, 49, 47)"><em>Combined hypogonadism is characterized by low serum T levels and/ or impaired spermatogenesis, with gonadotropin levels which vary depending on whether primary or secondary hypogonadism predominates. Late-onset hypogonadism (LOH) is an example of combined hypogonadism. It is a clinical and biochemical syndrome associated with advancing age characterized by symptoms indicative of androgen deficiency and a decline in serum T levels. </em></span>Accordingly, several cross-sectional and longitudinal studies have shown a gradual decline in T levels with increasing age, at an average rate of 1-2% per year,3, 4 which varies among men on the basis of the presence of adiposity, pharmacological therapies, and chronic diseases. Among a cohort of 3219 participants from Europe aged 40-79 years, LOH was identified in 2.1%, whereas 17% has shown isolated T deficiency (total T<11 nmol/L [317 ng/dL]).3, 4<em><span style="color: rgb(44, 130, 201)"> Finally, a new classification of hypogonadism has been proposed by using data from the European Male Ageing Study (EMAS), which presents the issue of “<u>compensated hypogonadism</u>,” a further clinical subgroup characterized by normal total T levels combined with higher LH values, especially in the aging population. This category of patients may develop infertility since their testicular dysfunction carries on an increased risk of low total motile sperm count, low testicular volume, and azoospermia.5 </span></em></p><p></p><p><span style="color: rgb(184, 49, 47)"><em><u><strong>Diagnosis of male hypogonadism is established when the presence of specific symptoms and signs are associated with decreased serum T levels</strong></u><strong>. </strong></em></span><span style="color: rgb(44, 130, 201)"><em><strong>So far 12.1 nmol/L (350 ng/dL or 3.5 ng/ mL) is considered the lower limit of the normal range for total T level.6 <u>However, due to individual differences in T sensitivity, some men may exhibit symptoms of hypogonadism with total T concentrations above this threshold</u>.6 </strong></em></span></p><p></p><p></p><p><em><span style="color: rgb(184, 49, 47)">Evidence strongly supports that low T is an important biomarker for morbidity and mortality in men.</span></em> <em><span style="color: rgb(44, 130, 201)"><u>It is now clear that low T levels correlate significantly with certain conditions, such as age, obesity, poor general health, and with some diseases, such as metabolic syndrome and cardiovascular disease (CVD)</u>.7</span></em><span style="color: rgb(184, 49, 47)"><em> Epidemiological studies identified T deficiency as a risk factor for CVD.8 Low levels of T may have important long-term negative health consequences, such as premature death, in presence of CVD, due to high rate of myocardial infarction, ischemic stroke, and other adverse cardiovascular events. It seems that patients with low T have a 24-124% increased risk for all-cause mortality during an average 4 to 16-year follow-up period.9, 10 Moreover, low T is significantly associated with respiratory mortality and to cancer mortality.10, 11</em></span> <span style="color: rgb(44, 130, 201)"><em>Lastly, normal serum T levels favor glycemic homeostasis through a better glucose uptake, utilization and disposal, and the general improvement of metabolism. For this reason, T deficiency favors hyperglycemia which, in addition to being the hallmark of diabetes mellitus, is an important component of the metabolic syndrome and increases the risk of CVD.12</em></span> <em><span style="color: rgb(184, 49, 47)">T deficiency has also been shown to alter the lipid profile and to change, by causing insulin-resistance, body composition favoring the accumulation of visceral fat.13 </span></em></p><p></p><p><span style="color: rgb(44, 130, 201)"><strong><em><u>Complications of untreated hypogonadism include worsening of sexual symptoms, bone damage, systemic symptoms, and long-term metabolic complications</u>.</em></strong> <em><strong>This strongly highlights the importance of proper pharmacological treatment of male hypogonadism. </strong></em><strong><em>Therefore, the aim of this review is to provide a comprehensive and updated overview of the available therapeutic options for male hypogonadism, including T, human chorionic gonadotropin (hCG), selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and their management.</em></strong></span></p><p></p><p></p><p><strong>Treatment of primary hypogonadism: <span style="color: rgb(184, 49, 47)">Testosterone formulations </span></strong></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Oral administration </strong></span></p><p></p><p><strong><span style="color: rgb(0, 0, 0)">Buccal administration </span></strong></p><p><strong><span style="color: rgb(0, 0, 0)"></span></strong></p><p><strong><span style="color: rgb(0, 0, 0)">Nasal administration </span></strong></p><p><strong><span style="color: rgb(0, 0, 0)"></span></strong></p><p><strong><span style="color: rgb(0, 0, 0)">Subdermal administration </span></strong></p><p></p><p><span style="color: rgb(0, 0, 0)"><strong>Transdermal testosterone</strong> </span></p><p><span style="color: rgb(184, 49, 47)">Transdermal patch </span></p><p><span style="color: rgb(184, 49, 47)">Transdermal gel/liquid solution</span></p><p></p><p><strong>Intramuscular administration</strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Treatment of central hypogonadism </strong></p><p><span style="color: rgb(184, 49, 47)">hCG </span></p><p><span style="color: rgb(184, 49, 47)">SERMs </span></p><p><span style="color: rgb(184, 49, 47)">AIs</span></p><p></p><p><strong>Treatment of prepubertal male hypogonadism: <span style="color: rgb(184, 49, 47)">the induction of puberty </span></strong></p><p><strong></strong></p><p><strong>Follow-up </strong></p><p><span style="color: rgb(184, 49, 47)">Follow-up of primary hypogonadism </span></p><p></p><p><strong>Management of central hypogonadism treatment</strong></p><p><strong></strong></p><p><strong>Exercise-related hypogonadism </strong></p><p><strong></strong></p><p><strong>Anabolic-androgenic steroids use </strong></p><p><strong></strong></p><p><strong>Treatment of the exercise-related hypogonadism </strong></p><p><strong></strong></p><p><strong></strong></p><p><strong>Conclusions </strong></p><p><strong></strong></p><p><strong><em><span style="color: rgb(184, 49, 47)">In conclusion, several therapeutic schemes are available for the treatment of male hypogonadism, whose choice depends on the timing of disease onset and fertility issues.</span></em></strong> <em><span style="color: rgb(44, 130, 201)"><strong>Exercise-related hypogonadism is still a controversial occurrence and it is unclear if a clinical intervention is warranted (or desired) since it is considered an adaptive condition with no reported negative health consequences.</strong></span></em> <span style="color: rgb(184, 49, 47)"><em><strong>Timing of follow-up, including the assessment of serum T levels and markers of safety, depending on the drug pharmacokinetics. </strong></em></span></p></blockquote><p></p>
[QUOTE="madman, post: 191269, member: 13851"] [B]Male hypogonadism: [COLOR=rgb(184, 49, 47)]therapeutic choices and pharmacological management[/COLOR] [/B] [COLOR=rgb(44, 130, 201)]Sandro LA VIGNERA, Giulia IZZO, Gian P. EMERENZIANI, Rossella CANNARELLA , Rosita A. CONDORELLI, Aldo E. CALOGERO, Antonio AVERSA [/COLOR] [B]ABSTRACT[/B] [I][COLOR=rgb(184, 49, 47)]Male hypogonadism, defined as an inadequate testosterone production, recognizes a testicular (primary hypogonadism) or a hypothalamic-pituitary dysfunction (central hypogonadism), although combined forms can also occur. [/COLOR][/I][COLOR=rgb(44, 130, 201)]Moreover, it has been known that intensive exercise training might be a cause of functional hypogonadism. [/COLOR][COLOR=rgb(184, 49, 47)][I]Many therapeutic choices are currently available, depending on the timing of hypogonadism onset and fertility issues. [/I][/COLOR][COLOR=rgb(44, 130, 201)][I]The aim of this review was to comprehensively supply therapeutic options and schemes currently available for male hypogonadism, including pharmacological management of primary and central forms. Evidence on testosterone formulations, human chorionic gonadotropin, selective estrogen receptor modulators, and aromatase inhibitors will be provided.[/I][/COLOR] [COLOR=rgb(184, 49, 47)][I]Male hypogonadism is a clinical syndrome characterized by failure of the testes to produce an adequate amount of testosterone (T) and/or a normal number of spermatozoa.[/I][/COLOR] [COLOR=rgb(44, 130, 201)][I]It can be classified according to the site of hypothalamic-pituitary dysfunction, the involvement of testicular cell population, and the time of its onset. [/I][/COLOR][COLOR=rgb(184, 49, 47)][I]Also, hypogonadism can be organic or dysfunctional. The former is caused by congenital, structural or destructive disorders, whereas the latter refers to potentially reversible conditions.1[/I][/COLOR] [COLOR=rgb(44, 130, 201)][I]Hypogonadism is further classified into primary or central forms, based on the presence of a dysfunction at the testicular or the hypothalamic-pituitary level.1, 2[/I][/COLOR] [COLOR=rgb(184, 49, 47)][I]Combined hypogonadism is characterized by low serum T levels and/ or impaired spermatogenesis, with gonadotropin levels which vary depending on whether primary or secondary hypogonadism predominates. Late-onset hypogonadism (LOH) is an example of combined hypogonadism. It is a clinical and biochemical syndrome associated with advancing age characterized by symptoms indicative of androgen deficiency and a decline in serum T levels. [/I][/COLOR]Accordingly, several cross-sectional and longitudinal studies have shown a gradual decline in T levels with increasing age, at an average rate of 1-2% per year,3, 4 which varies among men on the basis of the presence of adiposity, pharmacological therapies, and chronic diseases. Among a cohort of 3219 participants from Europe aged 40-79 years, LOH was identified in 2.1%, whereas 17% has shown isolated T deficiency (total T<11 nmol/L [317 ng/dL]).3, 4[I][COLOR=rgb(44, 130, 201)] Finally, a new classification of hypogonadism has been proposed by using data from the European Male Ageing Study (EMAS), which presents the issue of “[U]compensated hypogonadism[/U],” a further clinical subgroup characterized by normal total T levels combined with higher LH values, especially in the aging population. This category of patients may develop infertility since their testicular dysfunction carries on an increased risk of low total motile sperm count, low testicular volume, and azoospermia.5 [/COLOR][/I] [COLOR=rgb(184, 49, 47)][I][U][B]Diagnosis of male hypogonadism is established when the presence of specific symptoms and signs are associated with decreased serum T levels[/B][/U][B]. [/B][/I][/COLOR][COLOR=rgb(44, 130, 201)][I][B]So far 12.1 nmol/L (350 ng/dL or 3.5 ng/ mL) is considered the lower limit of the normal range for total T level.6 [U]However, due to individual differences in T sensitivity, some men may exhibit symptoms of hypogonadism with total T concentrations above this threshold[/U].6 [/B][/I][/COLOR] [I][COLOR=rgb(184, 49, 47)]Evidence strongly supports that low T is an important biomarker for morbidity and mortality in men.[/COLOR][/I] [I][COLOR=rgb(44, 130, 201)][U]It is now clear that low T levels correlate significantly with certain conditions, such as age, obesity, poor general health, and with some diseases, such as metabolic syndrome and cardiovascular disease (CVD)[/U].7[/COLOR][/I][COLOR=rgb(184, 49, 47)][I] Epidemiological studies identified T deficiency as a risk factor for CVD.8 Low levels of T may have important long-term negative health consequences, such as premature death, in presence of CVD, due to high rate of myocardial infarction, ischemic stroke, and other adverse cardiovascular events. It seems that patients with low T have a 24-124% increased risk for all-cause mortality during an average 4 to 16-year follow-up period.9, 10 Moreover, low T is significantly associated with respiratory mortality and to cancer mortality.10, 11[/I][/COLOR] [COLOR=rgb(44, 130, 201)][I]Lastly, normal serum T levels favor glycemic homeostasis through a better glucose uptake, utilization and disposal, and the general improvement of metabolism. For this reason, T deficiency favors hyperglycemia which, in addition to being the hallmark of diabetes mellitus, is an important component of the metabolic syndrome and increases the risk of CVD.12[/I][/COLOR] [I][COLOR=rgb(184, 49, 47)]T deficiency has also been shown to alter the lipid profile and to change, by causing insulin-resistance, body composition favoring the accumulation of visceral fat.13 [/COLOR][/I] [COLOR=rgb(44, 130, 201)][B][I][U]Complications of untreated hypogonadism include worsening of sexual symptoms, bone damage, systemic symptoms, and long-term metabolic complications[/U].[/I][/B] [I][B]This strongly highlights the importance of proper pharmacological treatment of male hypogonadism. [/B][/I][B][I]Therefore, the aim of this review is to provide a comprehensive and updated overview of the available therapeutic options for male hypogonadism, including T, human chorionic gonadotropin (hCG), selective estrogen receptor modulators (SERMs), aromatase inhibitors (AIs) and their management.[/I][/B][/COLOR] [B]Treatment of primary hypogonadism: [COLOR=rgb(184, 49, 47)]Testosterone formulations [/COLOR][/B] [COLOR=rgb(0, 0, 0)][B]Oral administration [/B][/COLOR] [B][COLOR=rgb(0, 0, 0)]Buccal administration Nasal administration Subdermal administration [/COLOR][/B] [COLOR=rgb(0, 0, 0)][B]Transdermal testosterone[/B] [/COLOR] [COLOR=rgb(184, 49, 47)]Transdermal patch Transdermal gel/liquid solution[/COLOR] [B]Intramuscular administration Treatment of central hypogonadism [/B] [COLOR=rgb(184, 49, 47)]hCG SERMs AIs[/COLOR] [B]Treatment of prepubertal male hypogonadism: [COLOR=rgb(184, 49, 47)]the induction of puberty [/COLOR] Follow-up [/B] [COLOR=rgb(184, 49, 47)]Follow-up of primary hypogonadism [/COLOR] [B]Management of central hypogonadism treatment Exercise-related hypogonadism Anabolic-androgenic steroids use Treatment of the exercise-related hypogonadism Conclusions [I][COLOR=rgb(184, 49, 47)]In conclusion, several therapeutic schemes are available for the treatment of male hypogonadism, whose choice depends on the timing of disease onset and fertility issues.[/COLOR][/I][/B] [I][COLOR=rgb(44, 130, 201)][B]Exercise-related hypogonadism is still a controversial occurrence and it is unclear if a clinical intervention is warranted (or desired) since it is considered an adaptive condition with no reported negative health consequences.[/B][/COLOR][/I] [COLOR=rgb(184, 49, 47)][I][B]Timing of follow-up, including the assessment of serum T levels and markers of safety, depending on the drug pharmacokinetics. [/B][/I][/COLOR] [/QUOTE]
Insert quotes…
Verification
Post reply
Share this page
Facebook
Twitter
Reddit
Pinterest
Tumblr
WhatsApp
Email
Share
Link
Sponsors
Forums
Testosterone Replacement, Low T, HCG, & Beyond
Testosterone and Men's Health Articles
Male Hypogonadism- Low Testosterone: Treatment Choices
This site uses cookies to help personalise content, tailor your experience and to keep you logged in if you register.
By continuing to use this site, you are consenting to our use of cookies.
Accept
Learn more…
Top